Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $34.17 Average PT from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.4167.

A number of analysts have commented on DYN shares. Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They set an “overweight” rating for the company. Morgan Stanley reduced their price target on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. TD Cowen began coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th.

Insider Transactions at Dyne Therapeutics

In other news, Director Brian S. Posner acquired 2,500 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $17.12 per share, with a total value of $42,800.00. Following the purchase, the director directly owned 18,000 shares of the company’s stock, valued at $308,160. The trade was a 16.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jason P. Rhodes sold 480,240 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the transaction, the director owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. This represents a 35.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,642,038 shares worth $35,898,156. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after buying an additional 14,727,667 shares during the period. Vanguard Group Inc. raised its stake in Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after buying an additional 1,455,151 shares during the period. State Street Corp lifted its holdings in Dyne Therapeutics by 27.0% during the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after acquiring an additional 1,423,828 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Dyne Therapeutics by 45.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new position in Dyne Therapeutics during the fourth quarter worth about $93,926,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Up 0.2%

Shares of NASDAQ:DYN opened at $25.24 on Tuesday. Dyne Therapeutics has a one year low of $9.89 and a one year high of $26.26. The company has a 50 day moving average of $21.39 and a 200-day moving average of $18.93. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The stock has a market cap of $4.71 billion, a price-to-earnings ratio of -7.58 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, sell-side analysts forecast that Dyne Therapeutics will post -3.28 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.